Acetylcysteine zidrimer
Identification
- Generic Name
- Acetylcysteine zidrimer
- DrugBank Accession Number
- DB16496
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- Acetylcysteine zidrimer
- Dendrimer N-acetyl-cysteine
- OP 101
- OP-101
- External IDs
- OP-101
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
OP-101 is a novel compound that involves n-acetyl cyseine covalently bonded to an inactive dendrimer. In preclinical models, it was shown that OP-101 is selectively taken up by activated microglia, and localizes in areas wehre there is neuroinflammation. In these activated neural cells, OP-101 releases n-acetyl cysteine and helps reduce oxidative stress and inflammation. In multiple animal models, OP-101 was shown to normalize reactive macrophages, shut down cytokine cascades, and attenuate hyperinflammation. Thus, in May 2020, Orpheris, a subsidiary of Ashvattha Therapeutics and the developer of the compound, is pursuing a Phase 2 clinical study on the safety, pharmacokinetics, and efficacy of OP-101 in patients exhibiting severe COVID-19 symptoms (NCT04458298).
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7JWF1EYH61
- CAS number
- 2736440-65-4
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) 1 1 Completed Treatment Healthy Volunteers (HV) 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at January 21, 2021 02:01 / Updated at June 20, 2023 09:00